Andere talen Kancera AB

Aandelen

KAN

SE0015658570

Vertraagde tijd Nasdaq Stockholm Andere beurzen 15:15:03 18-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,71 ^SEK	-2,29%		-2,84%	-62,38%

17/05	Kancera AB (publ) rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI
16/05	Kancera AB (publ) geeft een operationele update met betrekking tot de Kandova studie en meldt toegenomen patiëntenwerving	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Kancera - Underestimated optionality	22/05
Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851	17/05
Kancera AB Reports Earnings Results for the First Quarter Ended March 31, 2024	17/05
Kancera provides operational update regarding the KANDOVA study and reports increased patient recruitment	16/05
Kancera AB Provides Operational Update Regarding the Kandova Study and Reports Increased Patient Recruitment	16/05
Kancera appoints new Chief Scientific Officer and extends management team	08/05
Kancera AB Announces Executive Changes	08/05
Kancera meets the primary objectives of the KAND145 clinical phase I study	03/05
Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	03/05
Kancera announces the outcome of the company's rights issue	20/03
Kancera publishes prospectus in connection with the company’s rights issue	01/03
Kancera resolves on a rights issue of approximately SEK 121.9 million	23/02
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	23/02
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	23/02
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Kancera AB Signs A License Agreement with the University of Newcastle	23/02
Kancera AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	23/02
Kancera presents the statistical analysis of top line data from the FRACTAL study	06/02
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study	06/02
Kancera reports positive top line results from the FRACTAL study	20/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kancera AB

Aandelen

KAN

SE0015658570

Andere talen

Filters